# Cyrus Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyrus-biotechnology

- Industry: Software
- Headquarters: Seattle, US
- Website: www.cyrusbio.com
- Total disclosed funding: $26M
- Latest round: Series B (Feb 26, 2024)
- Investors on record: 12

## About

Founded in 2014 and based in Washington, US, Cyrus Biotechnology Inc. operates as a software company that offers a biologics discovery platform. The company was founded by David Baker. In December 2021, Cyrus Biotechnology Inc. raised USD 18 million in Series B funding from Agent Capital, Select Fund Management, Selecta Biosciences, Inc., and The Yard Ventures. As of 2023, the company is led by its CEO, Lucas Nivon.

Cyrus Biotechnology’s product line includes Cyrus Bench, which is a Rosetta-based protein design software that consists of a molecular modeling and design toolkit to solve protein engineering and structure prediction problems with the help of artificial intelligence; Cyrus API, which is a cloud-based platform for computational modeling and bioinformatics; deimmunization, a machine learning-based protein design platform for eliminating the immunogenicity of therapeutic proteins; and Cyrus’s protein biochemistry platform that uses deep mutational scanning and selection to explore the mutational landscape of proteins. The firm’s pipeline portfolio includes CRISPR (clustered, regularly interspaced short palindromic repeats), a bacterial enzyme system; ACE2, which is a protein-based therapeutic for COVID-19; and a treg-selective IL-2 protein agonist (IL-2).

## Funding rounds

- Series B, Feb 26, 2024 — Alumni Ventures Group
- Series B, Dec 1, 2021, $18M — OrbiMed Advisors, Trinity Ventures, Alexandria Venture Investments, WRF Capital, Selecta Biosciences, Inc., The W Fund, iSelect Fund Management, Alumni Ventures Group, Agent Capital, The Yard Ventures
- Series A, Jul 13, 2017, $8M — OrbiMed Advisors, Trinity Ventures, The W Fund, SpringRock Ventures, Sahsen Foundation

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Trinity Ventures (https://capitalatlas.ai/funds/trinity-ventures) — Series A, Series B
- The W Fund — Series A, Series B
- SpringRock Ventures (https://capitalatlas.ai/funds/springrock-ventures) — Series A
- Sahsen Foundation — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series B
- Selecta Biosciences, Inc. — Series B
- iSelect Fund Management (https://capitalatlas.ai/funds/iselect-fund-management) — Series B
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series B
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series B
- The Yard Ventures — Series B